Home

Troy Cox

CIK 1696923 · Executive Chair · last filed 2026-07-28

Troy Cox is an Executive Chair who has filed 30 SEC Form 4 insider transactions across 6 companies since 2017. The most recent filing shows the insider bought $148.7K of MPLT on Jul 28, 2026. Across all open-market trades the lifetime net is −$2.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.42M

Companies

6

Total Filings

30

Lifetime Open-Market Net

-$2.83M

Filer Profile

Reported Address
C/O FOUNDATION MEDICINE, INC.
C/O FOUNDATION MEDICINE, INC., 150 SECON
CAMBRIDGE, MA 02141
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MPLT Director 23,484 $13.00 $305.3K $148.7K 2 2026-07-28
LAB Director 475,702 $0.69 $328.2K $0 7 2026-06-23
SOPH Director 328,743 $7.87 $2.59M $0 1 2026-06-22
ZYME Director 7,500 $26.24 $196.8K $348.8K 6 2024-12-12
SomaLogic, Inc. (SLGCW) Delisted Executive Chair 106,930 $0.09 $9.2K $0 5 2023-03-22
Foundation Medicine, Inc. (FMI) Delisted Chief Executive Officer 242,068 — — -$3.33M 7 2018-07-05

Recent Filings

30 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-28 MPLT Buy (P) +15,620 $148.7K EDGAR
2026-06-25 MPLT Grant (A) +7,864 $0 EDGAR
2026-06-23 LAB Grant (A) +99,116 $0 EDGAR
2026-06-22 SOPH Grant (A) +19,724 $107.7K EDGAR
2026-03-02 LAB Grant (A) +57,264 $67.0K EDGAR
2025-07-30 LAB — — $0 EDGAR
2025-06-24 LAB Grant (A) +94,592 $0 EDGAR
2025-03-04 LAB Grant (A) +62,910 $67.0K EDGAR
2024-12-12 ZYME Grant (A) — $0 EDGAR
2024-07-02 LAB Grant (A) +43,128 $0 EDGAR
Showing 1–10 of 30
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.